transarterial radioembolization (TARE)

PROCEDURE2 trials

Sponsors

Seoul National University Hospital, AstraZeneca

Conditions

Hepatocellular CarcinomaHepatocellular Carcinoma (HCC)

Phase 2

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

Active, not recruitingNCT06040099

AstraZenecaHepatocellular Carcinoma (HCC)

Start: 2024-02-13End: 2026-07-01Updated: 2026-03-19

Phase 3

A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma

WithdrawnNCT02004210

Seoul National University HospitalHepatocellular Carcinoma

Start: 2013-04-30End: 2018-04-30Updated: 2016-04-27

Related Papers

EMERALD-Y90: A phase 2 study to evaluate transarterial radioembolization (TARE) followed by durvalumab (D) and bevacizumab (B) for the treatment of participants (pts) with unresectable hepatocellular carcinoma (uHCC) eligible for embolization.

Journal of Clinical Oncology2025-05-282 citations